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Alcoholic liver disease (ALD) develops in a subset of heavy drinkers (HDs). The goals of our study were to (1) 
characterize the global serum metabolomic changes in well-characterized cohorts of controls (Cs), HDs, and those 
with alcoholic cirrhosis (AC); (2) identify metabolomic signatures as potential diagnostic markers, and (3) determine 
the trajectory of serum metabolites in response to alcohol abstinence. Serum metabolic profiling was performed in 
22 Cs, 147 HDs, and 33 patients with AC using ultraperformance liquid chromatography–tandem mass spectrome-
try. Hepatic gene expression was conducted in Cs (n = 16) and those with AC (n = 32). We found progressive changes 
in the quantities of metabolites from heavy drinking to AC. Taurine-conjugated bile acids (taurocholic acid [TCA], 
127-fold; taurochenodeoxycholic acid [TCDCA], 131-fold; and tauroursodeoxycholic acid, 56-fold) showed more 
striking elevations than glycine-conjugated forms (glycocholic acid [GCA], 22-fold; glycochenodeoxycholic acid 
[GCDCA], 22-fold; and glycoursodeoxycholic acid [GUDCA], 11-fold). This was associated with increased liver cy-
tochrome P450, family 7, subfamily B, member 1 and taurine content (more substrates); the latter was due to dys-
regulation of homocysteine metabolism. Increased levels of GCDCA, TCDCA, GCA, and TCA positively correlated 
with disease progression from Child-Pugh A to C and Model for End-Stage Liver Disease scores, whereas GCDCA, 
GCA, and GUDCA were better predictors of alcohol abstinence. The levels of glucagon-like peptide 1 (GLP-1) and 
fibroblast growth factor (FGF) 21 but not FGF19 were increased in HDs, and all three were further increased in 
those with AC. Conclusion: Serum taurine/glycine-conjugated bile acids could serve as noninvasive markers to predict 
the severity of AC, whereas GLP-1 and FGF21 may indicate a progression from heavy drinking to AC. (Hepatology 
Communications 2019;3:542-557).
Excessive alcohol use can lead to adverse health outcomes that result in significant social and economic burdens.(1) Alcohol-related health 
disorders are generally determined by the quantity 
of alcohol consumed and the pattern of drinking.(2) 
Excessive alcohol use is associated with cancers, car-
diovascular disease, pancreatitis, and alcoholic liver 
disease (ALD).(3)
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alcoholic cirrhosis; AH, alcoholic hepatitis; ALD, alcoholic liver disease; ANOVA, analysis of variance; BA, bile acid; BAL, bile acid coenzyme A ligase; 
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ALD comprises a spectrum of disorders and his-
topathologic changes in individuals with acute and 
chronic alcohol consumption, ranging from alcoholic 
steatosis to alcoholic hepatitis (AH) and alcoholic cir-
rhosis (AC).(4) Alcoholic steatosis occurs almost uni-
versally in those with excessive alcohol use.(5) Once 
developed, it can progress to steatohepatitis, fibrosis, 
and cirrhosis.(6,7) Alcoholic steatosis is reversible with 
abstinence(5); however, continued drinking can lead 
to AC in up to 20% to 30% of excessive drinkers.(6,7) 
Evidence of a genetic component for the susceptibility 
to ALD has been described,(8,9) but a large variability 
remains unexplained, suggesting that other factors in 
addition to a genetic component might be involved in 
the disease process.
Excessive alcohol use interferes with the absorption, 
metabolism, transport, and excretion of nutrients.(10) 
It can also lead to electrolyte imbalance and meta-
bolic changes.(11) Advancement of the disease during 
progression of ALD is accompanied by alterations in 
carbohydrate and lipid metabolism, as demonstrated 
in different models of mice fed with ethanol.(12,13) 
Metabolomics is an emerging new area of basic and 
translational research. A comprehensive analysis of 
the changes in the levels of metabolites in patients 
with excessive alcohol use and those with ALD may 
provide mechanistic insights into why only a subset 
of patients develop ALD. Recently, Harada et al.(14) 
reported global metabolomic profiling among patients 
with alcohol intake. Nineteen metabolites are associ-
ated with daily alcohol consumption. Among them, 
13 metabolites are involved in amino acid metabolism, 
three in carbohydrate metabolism, two in lipid metab-
olism, and one in cofactor and vitamin metabolism.(14) 
In addition, plasma levels of three metabolites, i.e., 
threonine, guanidinosuccinate, and glutamine, are 
strongly associated with markers of hepatic inflam-
mation, such as aspartate aminotransferase, suggesting 
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their potential link to alcohol-induced liver injury(14); 
however, the underlying mechanism and the trajec-
tory of these metabolites with alcohol abstinence were 
unclear in that study. Furthermore, metabolomic alter-
ations for ALD are based on the association of these 
metabolites with markers of hepatic enzymes in those 
with alcohol use and not from patients with a known 
diagnosis of ALD.(14)
The goals of our study are to (1) characterize the 
global metabolomic changes in a well-characterized 
cohort of controls (Cs), heavy/excessive drinkers 
(HDs), and those with AC; (2) identify metabolomic 
signatures as potential diagnostic markers linking the 
changes in serum metabolomes with gene expression 
in the liver tissues of patients with AC; and (3) deter-
mine the trajectory of serum metabolites in response 
to alcohol abstinence.
Participants and Methods
ReCRuitment oF tHe stuDy 
CoHoRt
The study design was approved by the institutional 
review board at Indiana University Purdue University 
Indianapolis, Fairbanks Alcohol Rehabilitation Center, 
and Roudebush Veterans Administration Medical 
Center. Recruitments were performed in accordance 
with the relevant guidelines and regulations.
We enrolled 147 HDs from Fairbanks Drug and 
Alcohol Treatment Center (Indianapolis, IN). All 
fulfilled the definition of heavy drinking as defined 
by the National Institutes of Health (NIH)/National 
Institute on Alcohol Abuse and Alcoholism: >4 stan-
dard drinks in a day (or >14 per week) in men and 
>3 drinks in a day (or >7 per week) in women.(15) 
All participants were at least 21 years old and were 
excluded if they had active and serious medical dis-
eases, past history of jaundice or complications from 
portal hypertension, concurrent infection with viral 
hepatitis B or C, history of any infection within 4 
weeks, or recent surgeries within the past 3 months 
before enrollment.(16,17) We recruited 22 healthy Cs 
with no known history of heavy drinking from the 
Roudebush Veterans Administration Medical Center 
and enrolled 33 patients with known diagnosis of 
AC from the hepatology clinic at Indiana University. 
The detailed inclusion and exclusion criteria for AC 
have been described.(18) Of importance, patients with 
AC with ongoing infection, sepsis, or active gastro-
intestinal bleeding were excluded. To determine the 
levels of serum metabolites in response to alcohol 
abstinence, we prospectively recruited 24 HDs par-
ticipating in an alcohol treatment program. Blood 
was collected at baseline and at weeks 2 and 4 after 
alcohol abstinence. During this period, all partici-
pants complied with treatment, and none relapsed to 
alcohol use.
Human liVeR tissues
Coded human liver specimens from normal 
Cs (n = 16) and patients with AC (n = 32) were 
obtained through the Liver Tissue Cell Distribution 
System (Minneapolis, MN; NIH contract 
HSN276201200017C).(19-21) The use of coded liver 
tissues was reviewed and approved by the University 
of Connecticut institutional review board.
Data anD Biosample 
ColleCtion
Demographic information, clinical characteris-
tics, and laboratory tests were obtained at enroll-
ment. Participants also completed self-administered 
questionnaires, including Alcohol Use Disorders 
Identification Test-Concise (AUDIT-C) and Timeline 
Followback, to determine the quantity of alcohol con-
sumed over the 30 days before enrollment. The date of 
last alcohol consumption was also recorded. For those 
with AC, baseline Child-Pugh and Model for End 
Stage Liver Disease (MELD) scores were calculated. 
Blood was collected and centrifuged at 1,500g for 
10 minutes at 4°C. Serum was stored at −80oC until 
analysis.
Rna eXtRaCtion anD 
QuantitatiVe Real-time 
polymeRase CHain ReaCtion 
analyses
Total RNA isolation of human liver tissues was per-
formed using a commercially available RNA isolation 
kit. Complementary DNA synthesis was conducted 
as described.(22) Specific primers for quantitative 
real-time polymerase chain reaction (qRT-PCR) are 
shown in Supporting Table S1.
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sample pRepaRation anD 
metaBoliC pRoFiling
sample preparation
Metabolic profiling of serum samples was per-
formed, and analyses were carried out at Metabolon 
(Durham, NC). Samples from HDs were separated 
into two groups based on the duration of last alcohol 
consumption. Group one comprised HDs with the 
last alcohol consumption >10 days before enrollment 
(HD1); group two comprised HDs who continued to 
drink up to the time of enrollment (HD2). Samples 
were prepared using the automated MicroLab STAR 
system (Hamilton, Reno, NV). For quality control 
purposes, several recovery standards were added prior 
to the first step in the extraction process. To remove 
protein, small molecules bound to protein or trapped 
in the precipitated protein matrix were dissociated. 
To recover chemically diverse metabolites, proteins 
were precipitated with methanol under vigorous shak-
ing for 2 minutes (Glen Mills GenoGrinder 2000), 
followed by centrifugation. The resulting extract was 
divided into five fractions: two for analysis by two 
separate reverse phase (RP)/ultrahigh performance 
liquid chromatography–tandem mass spectroscopy 
(UPLC-MS/MS) methods with positive ion mode 
electrospray ionization (ESI), one for analysis by 
RP/UPLC-MS/MS with negative ion mode ESI, one 
for analysis by hydrophilic interaction liquid chro-
matography (HILIC)/UPLC-MS/MS with negative 
ion mode ESI, and one sample reserved for backup. 
Samples were placed briefly on a TurboVap (Zymark) 
to remove the organic solvent. Sample extracts were 
stored overnight in liquid nitrogen before preparation 
for analysis.
uplC-ms/ms
All methods used a Waters ACQUITY UPLC 
and a Thermo Scientific Q-Exactive high resolution/
accurate mass spectrometer interfaced with a heated 
ESI-II source and Orbitrap mass analyzer operated 
at 35,000 mass resolution. The sample extract was 
dried and then reconstituted in solvents compatible 
with each of the four methods. Each reconstitution 
solvent contained a series of standards at fixed con-
centrations to ensure injection and chromatographic 
consistency. One aliquot was analyzed using acidic 
positive ion conditions and chromatographically 
optimized for more hydrophilic compounds. In this 
method, the extract was gradient eluted from a C18 
column (Waters UPLC BEH C18-2.1 × 100 mm, 
1.7 µm) using water and methanol, containing 0.05% 
perfluoropentanoic acid (PFPA) and 0.1% formic 
acid (FA). Another aliquot was also analyzed using 
acidic positive ion conditions but chromatographi-
cally optimized for more hydrophobic compounds. 
In this method, the extract was gradient eluted from 
the same aforementioned C18 column using meth-
anol, acetonitrile, water, 0.05% PFPA, and 0.01% 
FA and was operated at an overall higher organic 
content. Another aliquot was analyzed using basic 
negative ion-optimized conditions using a separate 
dedicated C18 column. The basic extracts were gra-
dient eluted from the column using methanol and 
water but with 6.5 mM ammonium bicarbonate at 
pH 8. The fourth aliquot was analyzed by negative 
ionization following elution from an HILIC col-
umn (Waters UPLC BEH Amide 2.1 × 150 mm, 
1.7 µm) using a gradient consisting of water and 
acetonitrile with 10 mM ammonium formate, pH 
10.8. The MS analysis alternated between MS and 
data-dependent multistage scans using dynamic 
exclusion. The scan range varied slighted between 
methods but covered 70-1,000 m/z. Raw data files 
were archived and extracted.
Data extraction and Compound 
identification
Metabolites were identified by automated compar-
ison of ion features in the experimental samples to 
a reference library of chemical standard entries that 
included retention time, molecular weight (m/z), pre-
ferred adducts, and in-source fragments as well as 
associated MS spectra. Metabolites were curated by 
visual inspection for quality control.
measuRement oF seRum 
FiBRoBlast gRoWtH FaCtoR 
19 anD 21 anD gluCagon-liKe 
peptiDe 1
Serum levels of fibroblast growth factor 19 
(FGF19) (catalog #DF1900; R&D Systems, 
Minneapolis, MN), FGF21 (catalog #DF2100; R&D 
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Systems), and glucagon-like peptide 1 (GLP-1) 
(catalog #EGLP-35K; Millipore, Burlington, MS) 
were conducted per the manufacturers’ protocols.
measuRement oF HepatiC 
tauRine anD glyCine
Levels of hepatic taurine and glycine were mea-
sured using the taurine (catalog #MET-5071) and 
glycine (catalog #MET-5070) assay kits (Cell Biolabs, 
Inc., San Diego, CA).
statistiCal analysis
We presented basic characteristics as mean ± 
SEM for continuous variables and as numbers with 
percentages for categorical variables. Appropriate 
comparisons, including chi-square test, Student t test, 
and analysis of variance (ANOVA), were used. For 
metabolomic data, we used significance tests and clas-
sification analysis. Standard statistical analyses were 
performed in ArrayStudio on log-transformed data. 
For those analyses not standard in ArrayStudio, the 
programs R or JMP were used. Biochemicals that dif-
fered significantly between experimental groups were 
determined using one-way and repeated measures 
ANOVA tests. Multiple comparisons were accounted 
for by estimating the false discovery rate using q val-
ues. Random forest (RF) analysis was performed to 
bin individual samples into groups based on the sim-
ilarities and differences of metabolites. P ≤ 0.05 was 
Fig. 1. Metabolic profiling of sera. (A) Hierarchical clustering displays differentiation of serum metabolites among study groups. 
Color scale demonstrates relative expression of metabolites across all samples. A majority of AC samples cluster to the right; control 
samples tend to cluster more to the left but are interspersed with HD1 and HD2 samples. (B) PCA of all serum samples with two views 
of the 3D plot. PCA differentiated AC serum from control and HD sera. (C) 2D PCA based on global metabolite profiles in the HD1 
and HD2 samples.
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considered statistically significant, and P < 0.10 was 
reported as trends.
Results
Baseline DemogRapHiCs anD 
CliniCal CHaRaCteRistiCs oF 
tHe stuDy CoHoRt
The detailed demographic and clinical character-
istics of the study cohort are shown in Supporting 
Table S2. Patients with AC were older (mean age, 
53.7 years old) compared to other groups (P = 0.001). 
No differences in sex and races were observed among 
the four study cohorts. As expected, patients with 
AC had the lowest levels of hemoglobin (11.9 g/dL), 
platelet counts (135.1 × 103 cell/mm3), and serum 
albumin (3.2 g/dL) (P = 0.0001); this group also had 
the highest levels of serum bilirubin (3.3 mg/dL) and 
creatinine (1.14 mg/dL) (P = 0.0001).
CompaRatiVe metaBolomiC 
pRoFiles in Cs, HDs, anD 
patients WitH alD
The data set comprises a total of 773 compounds 
of known identity in serum. A summary of the 
numbers of biochemicals that achieved statistical 
significance (P ≤ 0.05) as well as those approaching 
significance (0.05 < P < 0.10) is shown in Supporting 
Table S3. Using one-way ANOVA, we observed sig-
nificant differences in metabolomic profiles among 
groups. We used hierarchical clustering to demon-
strate the differentiation of metabolites in our study 
cohorts (Fig. 1A). A majority of AC samples clus-
tered to the right of the plot. C samples tended to 
cluster more to the left but were interspersed with 
HD1 and HD2. Principal component analysis 
(PCA) was then performed using all serum samples 
with two views of the three-dimensional (3D) plot 
(Fig. 1B). PCA differentiated the AC sera from Cs 
and HDs. There appeared to be some partial seg-
regation of C sera from HD1 and HD2 samples. 
Differentiation of HD1 from HD2 sera was not 
evident in the 3D plot. To further explore potential 
differences in the HD1 and HD2 samples based 
on global metabolic profiles, a 2D PCA was con-
ducted (Fig. 1C). Although not impressive, there 
appeared to be some skewing of the HD2 samples 
lower on the y axis. We then used RF analysis to bin 
individual samples into groups based on the simi-
larities and differences of metabolites (Supporting 
Fig. S1). RF analysis of the serum groups resulted 
in an overall predictive accuracy of 63%. C and AC 
samples were binned with the greatest accuracy; HD1 
and HD2 samples were frequently mis-segregated 
to the alternate HD group or C group. The top 30 
metabolites that most strongly contributed to bin-
ning of individual samples into groups are shown in 
Supporting Fig. S1. Metabolites with higher “mean 
decrease accuracy” values contributed more strongly 
to group differentiation. The top two metabolites in 
mean decrease accuracy were 7-methylguanidine, a 
modified nucleobase that is possibly derived from 
nucleotide degradation, and cystine, an oxidized 
dimer of cysteine molecules. Metabolites in the bile 
acid (BA) pathway were also identified in the top 30 
by using RF analysis (Supporting Fig. S1).
seRum tauRine-ConJugateD 
Bas WeRe stRiKingly eleVateD 
in HDs anD patients WitH aC
BAs are produced in the liver and secreted into 
the intestine where a significant portion are decon-
jugated and structurally modified into secondary BAs 
by intestinal bacteria. Both primary (Fig. 2A) and sec-
ondary (Fig. 2B) BAs were elevated in HD1 and HD2 
sera relative to Cs, although not all increases achieved 
statistical significance (Supporting Table S4; Fig. 2). 
Although our HD cohort had no clinically apparent 
AC, we observed that a subset of these patients in fact 
had a slight elevation of transaminases (Supporting 
Table S2). Interestingly, we found that those with 
abnormal transaminases (using the laboratory cutoff 
of 40 U/L) had significantly higher levels of glycoche-
nodeoxycholic acid (GCDCA) sulfate, taurocholenate 
sulfate, glycocholenate sulfate, and glycodeoxycho-
late (GDCA) sulfate compared to those with normal 
transaminases.
Serum levels of primary BAs (Fig. 2A), such as 
cholic acid (CA), glycocholic acid (GCA), tauro-
cholic acid (TCA), chenodeoxycholic acid (CDCA), 
GCDCA, taurochenodeoxycholic acid (TCDCA), 
tauro-beta-muricholate, and GCDCA sulfate, were 
significantly higher in AC sera. Similar observations 
in the increase in levels of secondary BAs were also 
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found in patients with AC (Fig. 2B). It was noted that 
taurine-conjugated BAs (TCA, TCDCA, taurour-
sodeoxycholic acid [TUDCA]) showed a more strik-
ing elevation than glycine-conjugated forms (GCA, 
GCDCA, glycoursodeoxycholic acid [GUDCA]). 
Increases in serum BAs may reflect increased synthe-
sis because we found that the BA synthesis interme-
diate 7 alpha-hydroxy-3-oxo-4-cholestenoic acid was 
sharply higher in AC sera relative to all other groups 
(Supporting Fig. S2).
HepatiC CytoCHRome 
p450, Family 7, suBFamily B1 
eXpRession in tHe aCiDiC 
patHWay oF Ba syntHesis Was 
signiFiCantly eleVateD in 
patients WitH alD
To further determine the mechanism underly-
ing the alterations in serum BA levels, we measured 
the levels of gene expression involved in BA synthe-
sis in the liver of patients with AC. Expression of 
rate-limiting enzymes in the neutral pathway of BA 
biosynthesis microsomal cholesterol 7α-hydroxylase 
(cytochrome P450 [CYP], family 7, subfamily A, 
member 1 [CYP7A1] and CYP, family 8, subfamily 
B, polypeptide 1 [CYP8B1]) as well as the enzyme 
in the acidic pathway CYP27A1, was markedly 
down-regulated in AC livers versus Cs (Fig. 2C, 
left). In contrast, hepatic messenger RNA (mRNA) 
expression of CYP7B1 in the acidic pathway was sig-
nificantly higher than Cs. Unconjugated BAs are con-
jugated with taurine by the liver-specific enzymes BA 
coenzyme A (CoA) ligase (BAL) and BA CoA:amino 
acid N-acyltransferase (BAT). Interestingly, BAL but 
not BAT was down-regulated in AC livers relative to 
Cs (Fig. 2C, right).
Among BA transporters, both export (bile salt 
export pump [BSEP], multidrug resistance- associated 
protein 2 [MRP], adenosine triphosphate binding 
Fig. 2. Primary and secondary BAs. Each Color represents a study group. Box plots demonstrating relative levels of (A) primary 
BAs and (B) secondary BAs among the study cohorts. (C-E) qRT-PCR of hepatic mRNA expression of genes related to (C) BA 
biosynthesis, (D) BA export and uptake, and (E) nuclear receptors regulating BA synthesis in controls and patients with AC. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (F) Serum levels of FGF19, FGF21, and GLP-1 in controls, HDs, and those with 
ALD. Abbreviations: CA, cholate; GCA, glycocholate; SHP, small heterodimer partner; TβMCA, tauro-beta-muricholate.
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cassette, subfamily G, member 5 and member 8 
[ABCG5, ABCG8]) and uptake (organic-anion-trans-
porting polypeptide [OATP] 1A2, OATP1B3, 
OATP2B1) genes were down-regulated in AC versus 
Cs (Fig. 2D). In addition, the levels of several nuclear 
receptors, including farnesoid X receptor (FXR), 
hepatocyte nuclear factor 4α (HNF4α), liver X recep-
tor (LXR), and pregnane X receptor (PXR), were 
markedly reduced in patients with AC (Fig. 2E).
seRum FgF21 anD glp-1 leVels 
WeRe maRKeDly eleVateD in 
HDs anD patients WitH alD
BAs in the intestine can also activate intestinal 
cells to release several hormones, such as FGF19 and 
GLP-1. Levels of FGF19 in HDs and Cs were com-
parable; however, they were significantly increased in 
patients with AC versus HDs (Fig. 2F, top). Levels 
of GLP-1 were significantly increased in HDs and 
patients with AC compared to Cs (Fig. 2F, bottom). 
We also measured FGF21 and found increased levels 
in HDs (442 ± 81.8 pg/mL) and in patients with AC 




WeRe signiFiCantly alteReD 
in patients WitH aC
Serum of patients with AC and to a lesser extent 
HD2 and HD1 sera displayed increases in metabolites 
from the homocysteine pathway (Supporting Table 
S5), including methionine, S-adenosylhomocysteine, 
cystathionine, and cysteine (Fig. 3A). The antioxidant 
glutathione is one of the primary molecules generated 
by cells to combat oxidative stress. We found levels 
of glutathione-related metabolites were lower in the 
serum of patients with AC relative to Cs (Fig. 3B), 
whereas serum taurine and glycine levels remained 
unaltered (Fig. 3C).
To establish potential correlations between the 
expression of genes involved in these pathways and 
Fig. 3. Box plots demonstrating relative levels of metabolites. (A) methionine metabolism; (B) glutathione metabolism. (C) Box plots 
of serum taurine and glycine. (D) qRT-PCR of hepatic mRNA expression of genes related to methionine metabolism, trans-sulfuration, 
and DNA methylation pathway in controls (n = 10, in duplicate) and those with ALD (n = 30). *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001. (E) Schematic diagram illustrating the methionine metabolism pathway. (F) Hepatic taurine and glycine concentration 
from controls (n = 12) and from those with ALD (n = 30). Abbreviations: AHCY, adenosylhomocysteinase; BHMT1, betaine-
homocysteine S-methyltransferase 1; CBS, cystathionine-beta-synthase; CDO1, cysteine dioxygenase type 1; CTH, cystathionine 
gamma-lyase; DNMT, DNA methyltransferase; GNMT, glycine N-methyltransferase; MTHFR, methylenetetrahydrofolate reductase; 
N5-MTHF, N5-methyltetrahydrofolate; PEMT, phosphatidylethanolamine methyltransferase; SAH, S-adenosylhomocysteine; 
SAM, S-adenosylmethionine; THF, tetrahydrofolate.
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levels of serum metabolites, we determined mRNA 
expression of major genes in the livers of Cs versus 
patients with AC. Interestingly, the majority of genes 
showed down-regulation (methionine adenosyltrans-
ferase 1A [MAT1A], adenosylhomocysteinase [AHCY], 
glycine N-methyltransferase, phosphatidylethanol-
amine methyltransferase [PEMT], cystathionine- 
beta-synthase, cysteine dioxygenase type 1), whereas 
methionine synthase (MTR) and cysteine sulfinic acid 
decarboxylase (CSAD) exhibited increased expression 
(Fig. 3D). Up-regulation of MTR and CSAD may 
contribute to elevated methionine and taurine synthe-
sis, respectively (Fig. 3E). Indeed, liver taurine content 
was markedly increased in the livers of patients with 
AC compared to C livers (Fig. 3F). It is plausible that 
dysregulation in homocysteine metabolism in the liv-
ers of patients with AC produced more taurine sub-
strate for conjugation to BAs, resulting in substantial 
elevation of taurine-conjugated BAs (Fig. 2A).
signiFiCant eleVation 
in Heme DegRaDation 
metaBolites in patients 
WitH aC
We also found that heme degradation metabo-
lites were elevated in sera of patients with AC rela-
tive to Cs and the HD groups (Supporting Table S6). 
Unconjugated bilirubin, derived from heme degra-
dation, circulates in the bloodstream and is removed 
from the circulation by the liver. Metabolomic anal-
ysis showed an elevation in serum bilirubin levels 
(Fig. 4A); this was consistent with patient character-
istics (Supporting Table S2). In addition, we observed 
an increase in serum levels of biliverdin and urobilino-
gen in patients with ALD. Conversion of biliverdin to 
bilirubin is under the control of biliverdin reductase A 
(BVRA), and its expression was increased in patients 
with AC (Fig. 4B).
Fig. 4. Metabolites in bilirubin, sulfated steroids, and branched-chain amino acids. (A) Box plots demonstrating the relative levels of 
metabolites in hemoglobin and bilirubin metabolism. (B) qRT-PCR of hepatic mRNA expression of the BVRA gene in controls and 
patients with AC and a schematic diagram illustrating heme metabolism. ***P < 0.001, ****P < 0.0001. (C) Box plots demonstrating 
relative levels of metabolites of the sulfated steroids dehydroisoandrosterone sulfate and androstenediol (3beta,17beta) disulfate.(1) 
(D) Hepatic mRNA expression of genes related to sulfated steroid metabolism and diagram demonstrating the correlated pathway. 
(E) Box plots demonstrating relative levels of metabolites in leucine, isoleucine, and valine metabolism and hepatic mRNA expression 
of the BCAT1 gene in controls and those with AC. (F) Schematic diagram illustrating the pathway of leucine, isoleucine, and valine 
metabolism. Abbreviations: BCKD, branched-chain alpha-ketoacid dehydrogenase complex; BLVRA/BLVRB, biliverdin reductase; 
CoA, coenzyme A; NADP, nicotinamide adenine dinucleotide phosphate; NADPH, nicotinamide adenine dinucleotide phosphate 
reduced form; TCA cycle, tricarboxylic acid cycle.
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ReDuCeD leVels oF sulFateD 
steRoiDs oBseRVeD in 
patients WitH aC
Interestingly, we found that sulfated steroids, such 
as dehydroisoandrosterone sulfate, were markedly 
decreased in AC sera relative to Cs (Supporting Table 
S7; Fig. 4C). Levels of androstenediol (3beta,7beta) 
disulfate,(1) on the other hand, were elevated in HD2 
but not in ALD sera. Expression of genes related 
to sulfuration (sulfotransferase [SULT] 1E1 and 
SULT2A1) was significantly decreased in liver tissues 
from patients with AC (Fig. 4D).
alteRations in leVels oF 
seRum BRanCHeD-CHain 
amino aCiD metaBolites in 
patients WitH aC
We found that serum levels of branched-chain 
amino acids (BCAAs) were reduced in patients with 
AC (Fig. 4E; Supporting Table S8) along with the 
α-ketoacids produced by BCAA transaminase (BCAT) 
in the first step of BCAA catabolism. Each BCAA 
was significantly reduced (e.g., isoleucine) along with 
its respective α-ketoacids, such as 3-methyl-2-oxoval-
erate (generated from isoleucine) (Fig. 4E,F). Hepatic 
expression of BCAT1 was significantly higher in 
patients with AC compared to Cs (Fig. 4E, right). 
Each BCAA was reduced to a statistically significant 
level (e.g., isoleucine) along with its α-ketoacid deriv-
ative 3-methyl-2-oxovalerate. The 2-hydroxycarbox-
ylic acids, such as 2-hydroxy-3-methylvalerate, were 
statistically increased in AC sera (Supporting Table 
S8; Supporting Fig. S3).
alteRations in tHe leVels oF 
seRum gluCose metaBolites 
in patients WitH aC
Glycolysis intermediates were altered in the serum 
of HDs and patients with AC compared to Cs 
(Supporting Fig. S4A,B). We found that glucose levels 
were statistically higher in AC sera. Coincident with 
the higher glucose levels, levels of 1,5-anhydrogluci-
tol (1,5-AG) were also lower relative to other groups. 
1,5-AG, a noninvasive marker indicative of the levels 
of serum glucose, circulates in the blood and is filtered 
by renal glomeruli. Renal reabsorption of 1,5-AG is 
inhibited by excess glucose, as shown by the reduced 
levels of 1,5-AG in AC. Pyruvate levels were slightly 
increased in AC sera (although not statistically signif-
icant), whereas serum lactate was significantly elevated 
in AC (Supporting Fig. S4B). We next determined the 
changes in metabolites related to the mitochondrial 
tricarboxylic acid cycle and found a significant increase 
in the metabolites (citrate, alpha-ketoglutarate, 
succinate, fumarate, and malate) in this pathway 
in AC and HD sera relative to Cs (Supporting 
Fig. S4C).
alteRations in tHe leVels 
oF seRum Fatty aCiD 
metaBolites in patients 
WitH alD
Serum levels of several long-chain fatty acids 
were significantly elevated in the serum of patients 
with AC; these included serum palmitate, palmi-
toleate, and eicosenoate (Supporting Table S9). 
Acylcarnitines are generated to permit the transfer 
of free fatty acids across the mitochondrial mem-
brane for β-oxidation. Interestingly, we found a sig-
nificant elevation of serum acylcarnitines in patients 
with AC.
tRaJeCtoRy oF seRum 
metaBolites in Response to 
alCoHol aBstinenCe
We demonstrated alterations of several serum 
metabolites in several metabolic pathways in HDs 
and patients with AC (Figs. 1‒4). To further test that 
changes in the levels of these metabolites were in 
response to alcohol, we prospectively followed the tra-
jectory of their levels in HDs participating in an alco-
hol treatment program. Serum metabolomic analyses 
were performed at baseline (immediately before start-
ing the program, week 0) and at the indicated times 
shown in Fig. 5. Among the metabolites being mea-
sured, we found that levels of GCDCA, GCA, GDCA, 
glycolithocholic acid, and GUDCA decreased signifi-
cantly with alcohol abstinence compared to baseline 
(Fig. 5A,B). On the other hand, homocysteine metab-
olites and heme degradation metabolites were not 
markedly altered by alcohol abstinence (Fig. 5C,D).
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seRum Bas among patients 
WitH aC stRatiFieD By 
Disease seVeRity
To determine the levels of BAs in patients with 
AC by severity, we compared their levels stratified by 
Child-Pugh classification (Supporting Table S10). 
Among primary BA metabolites, we found that only 
the levels of conjugated GCA (P = 0.02), TCA (P = 
0.01), GCDCA (P = 0.0001), and TCDCA (P = 0.007) 
were significantly increased during progression of the 
disease from Child-Pugh A to C. Interestingly, we 
did not observe any changes in the levels of secondary 
BAs by Child-Pugh classification except for glycohyo-
cholate (P = 0.04). The same trend was observed when 
we examined the levels of these metabolites in cor-
relation with MELD scores (Fig. 6). Serum GCDCA 
(P = 0.003) and TCDCA (P = 0.04) levels signifi-
cantly correlated with MELD scores, whereas GCA 
(P = 0.08) and TCA (P = 0.07) were less correlative.
Discussion
This study represents the first complete and com-
prehensive metabolic profiling of the largest cohort of 
human sera collected from well-characterized HDs and 
HDs with AC. It is also the first study to determine 
trajectory changes of metabolites in this cohort follow-
ing abstinence. Overall, metabolites produced from a 
wide range of pathways, including BAs, heme degrada-
tion products, sulfated steroids, fatty acids, tricarboxylic 
acid cycle, and BCAA metabolites, were significantly 
altered in HDs and in HDs with AC. We observed 
progressive changes in the quantities of metabolites 
from different metabolic pathways from HD1 to HD2 
and AC. The total number of significantly increased 
metabolites rose from 89 to 195 when the analyses 
were performed in HDs whose last alcohol consump-
tion was >10 days before enrollment compared to those 
who continued to drink up to the time of enrollment. 
This observation is of interest as we have previously 
shown that the timing of last alcohol consumption, 
especially within 10 days before enrollment, affects 
levels of circulating neutrophils and serum transami-
nase(23). Once AC developed, alterations in the number 
of metabolites were more profound, with a total of 282 
and 138 metabolites being increased and decreased, 
respectively, when compared to Cs.
Can seRum-ConJugateD 
Bas seRVe as noninVasiVe 
DiagnostiC maRKeRs FoR aC?
Three taurine-conjugated BAs were strikingly 
elevated more than 50-fold in AC serum relative 
Fig. 5. Trajectory of metabolites after alcohol abstinence. Trajectory of metabolites in the metabolism of (A) primary BAs, (B) secondary 
BAs, (C) methionine and glutathione, and (D) hemoglobin and bilirubin metabolism at baseline and at week 2 and week 4 after alcohol 
abstinence. Abbreviations: CA, cholate; GDCA, glycodeoxycholate; GLCA, glycolithocholic acid; SAH, S-adenosylhomocysteine; 
wk, week.
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to Cs; these were TCA (127-fold), TCDCA (131-
fold), and TUDCA (56-fold) (Fig. 2A,B). Glycine-
conjugated BAs (GCA, GCDCA, GUDCA) were 
elevated about 10-fold to 20-fold in AC versus C 
sera. Nonconjugated BAs (CA, CDCA) were ele-
vated less than 10-fold in AC serum. The results 
suggest increased liver BA synthesis, conjugation, or 
export.
Synthesis of BAs is initiated by oxidation of cho-
lesterol by two different pathways, the neutral path-
way and the acidic pathway.(24) Major BA synthesis 
enzymes CYP7A1 and CYP8B1 (neutral pathway) 
and CYP27A1 (acidic pathway)(25) were significantly 
down-regulated in AC livers (Fig. 2C, left), which 
could have been due to feedback inhibition of their 
expression by BAs. On the contrary, CYP7B1 (acidic 
pathway) showed a marked induction in the livers of 
patients with AC. Thus, CYP7B1 may be the key 
contributor to increased BA synthesis in patients, 
an assumption that should be mechanistically tested 
in a future study. In line with this observation, we 
found a progressive increase mainly in the subsets 
of conjugated primary (GCDCA, TCDCA, GCA, 
TCA) but not secondary (except for glycohyocho-
late) BA metabolites in parallel with disease severity 
in patients with AC (Fig. 6; Supporting Table S10).
BAL and BAT mediate the conjugation of CA 
and CDCA with taurine and glycine, respectively. 
Surprisingly, BAL expression was down-regulated 
whereas BAT expression showed no changes in the 
livers of patients with AC (Fig. 2C, right). Therefore, 
increased taurine- and glycine-conjugated BAs are 
unlikely to result from changes of BAL and BAT. 
Instead, the significantly increased liver taurine con-
tent (Fig. 3F) due to increased CSAD and taurine 
synthesis (Fig. 3E) would provide more substrates to 
generate taurine-conjugated BAs.
Another interesting observation was that most 
BA transporters, including export (BSEP, MRP2, 
ABCG5, ABCG8) and uptake (OATP1A2, 
Fig. 6. Linear regression analysis between the levels of BA and MELD scores.
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OATP1B3, OATP2B1), were all down-regulated 
in the livers of patients with AC (Fig. 2D), sug-
gesting an overall dysregulation. In addition, BAs 
serve as signaling molecules by activating nuclear 
receptor FXR in the liver.(26,27) Activation of FXR 
leads to inhibition of genes related to BA synthesis 
(CYP7A1, CYP8B1, CYP27A1, and CYP7B1)(28) 
through activation of the small heterodimer part-
ner.(29,30) Expression of liver receptor homolog 
1 (LRH1), HNF4a, LXR, and PXR was down- 
regulated in the livers of patients with AC (Fig. 2E), 
which may contribute to the decreased expression of 
CYP enzymes.
Can seRum FgF21 anD glp-1 
seRVe as pReDiCtiVe maRKeRs 
FRom HeaV y DRinKing to aC 
tRansition?
BAs can activate FXR in the intestine, leading 
to the release of FGF19 from enterocytes(31); this, 
in turn, inhibits BA synthesis through CYP7A1. 
Although FXR expression did not occur in the intes-
tine, levels of FGF19 were highly elevated in patients 
with AC versus Cs or HDs (Fig. 2F).
Another closely related nuclear receptor-regu-
lated FGF negatively regulating BA synthesis is 
FGF21.(26,32) BAs also act as the ligands for the G 
protein-coupled receptor (GPCR) TGR5.(33) Once 
activated, TGR5 stimulates the release of GLP-1 
from enterochromaffin L cells in the intestine.(34) 
LXR negatively regulates FGF21 expression. The 
increase in serum levels of FGF21 may be secondary 
to the inhibition of LXR in ALD(35) (Fig. 2E). Both 
FGF21 and GLP-1 were markedly elevated in HDs 
and further elevated in ALD relative to Cs. Thus, 
the increased levels of FGF21 and GLP-1 but not 
FGF19 are associated with the severity of alcoholic 
liver injury from heavy drinking to ALD.
At the time of this manuscript preparation, dys-
regulation of serum BAs and FGF19 was reported 
in patients with AH.(36) Interestingly, one common 
observation is the significant reduction in de novo 
BA synthesis gene CYP7A1 among patients with 
AH.(36) Our results (focusing on AC) provide com-
plementary support that alterations of BA homeo-
stasis may be a key factor driving the progression of 
ALD. Modulation of BA signaling and metabolism 
could represent a promising therapeutic strategy for 
the treatment of ALD.
HomoCysteine metaBolism 
is tHe seConD most seVeRely 
DisRupteD patHWay in 
patients WitH aC
Heavy alcohol consumption is known to disturb the 
methionine metabolic pathway.(37) High levels of serum 
methionine (Fig. 3A) are likely due to inhibition of 
hepatic MAT1A (Fig. 3D), similar to the results of a 
previous report.(38) A number of studies have shown that 
alcohol consumption reduces hepatic glutathione.(38-40) 
Interestingly, we observed significantly lower levels of 
glutathione-related metabolites in patients with ALD 
(Fig. 3B). Production of reactive oxygen species can lead 
to oxidation of metabolites and cellular countermea-
sures to reduce oxidative stress. We found that levels of 
the oxidized methionine species methionine sulfoxide 
and methionine sulfone were significantly increased in 
patients with AC (Fig. 3A). Cystine, representing an 
oxidized dimer of cysteine molecules, was also increased 
in HDs and patients with AC relative to Cs (Fig. 3A). 
Glutathione can be generated from methionine by cys-
tathionine and cysteine synthesis through the trans- 
sulfuration process (Fig. 3E). Although cystathionine 
was significantly increased in AC serum (Fig. 3A), this 
did not translate into elevated cysteine. If cystathionine 
and cysteine levels in sera reflect production of cysteine 
in the liver, there may be evidence for some restriction 
in cysteine production from cystathionine, although 
we did not observe an increase in the expression of 
hepatic cystathionine gamma-lyase in patients with AC 
(Fig. 3D,E). Dysregulation of methionine/homocysteine 
metabolism may lead to increased production of taurine, 
resulting in substantial elevation of taurine-conjugated 
instead of glycine-conjugated BAs (Fig. 2A). Indeed, a 
significant increase in the hepatic expression of CSAD 
(Fig. 3D,E) and hepatic taurine levels (Fig. 3F) was 
observed in patients with AC.
DisRuption oF otHeR 
metaBoliC patHWays in 
patients WitH aC
Levels of total bilirubin in our study cohort 
(Supporting Table S2) were significantly higher than 
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those of Cs and HDs; thus, alterations of several 
metabolites related to heme metabolism in patients 
with ALD (Fig. 4A) were expected. We also found 
that hepatic BVRA, a multifunctioning protein primar-
ily responsible for the reduction of biliverdin to bil-
irubin, was significantly up-regulated in patients with 
ALD (Fig. 4B). BVRA has been shown to attenuate 
hepatic steatosis(41); whether our observation is indic-
ative of the protective mechanism against alcohol- 
induced hepatic steatosis/liver injury in patients with AC 
should be further determined. Sulfation and desulfation 
are vital biological processes that regulate steroidogen-
esis and thus steroid hormone action in a variety of 
tissue.(42) We found that levels of several sulfated 
Fig. 7. Mechanistic illustration of the effect of alcohol on the dysregulation of genes involving several metabolic pathways leading 
to alterations in serum metabolomic profiles. The levels of taurine-conjugated BAs (TCA, TCDCA, and TUDCA) are markedly 
increased compared to glycine-conjugated forms (GCA, GCDCA, and GUDCA) in patients with AC. This is associated with an 
increase in hepatic CYP7B1 expression in the BA synthesis pathway and taurine content secondary to the dysregulation of homocysteine 
metabolism. Increased levels of GCDCA, TCDCA, GCA, and TCA are positively correlated with disease progression from Child-
Pugh A to C and MELD scores, whereas GCDCA, GCA, and GUDCA are better predictors following alcohol abstinence. Alcohol 
also inhibits the expression of several nuclear receptors, such as FXR, HNF4α, LXR, and PXR, and affects the serum levels of 
FGF19, FGF21, and GLP-1. An increase in the by-product of heme metabolism in the serum is associated with the induction of 
BVRA, whereas the inhibition of genes related to sulfuration, such as SULT1E1 and SULT2A1, leads to a reduction in serum-sulfated 
steroids. Abbreviations: AHCY, adenosylhomocysteinase; BHMT, betaine-homocysteine S-methyltransferase; CBS, cystathionine-
beta-synthase; CDO, cysteine dioxygenase; CTH, cystathionine gamma-lyase; DNMT, DNA methyltransferase; GNMT, 
glycine N-methyltransferase; MTHFR, methylenetetrahydrofolate reductase; N5-MTHF, N5-methyltetrahydrofolate; PEMT, 
phosphatidylethanolamine methyltransferase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate.
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steroids were significantly lower in patients with AC 
(Fig. 4C). Because steroid sulfation can occur in the 
liver, a reduction may reflect hepatic dysfunction as 
indicated by decreased hepatic expression of SULT (Fig. 
4D). However, a recent study reported the important 
role of SULT enzymes, notably SULT1E1, in regulat-
ing glucose and lipid metabolism.(43) Loss of SULT1E1 
function results in improving insulin sensitivity, which 
decreases hepatic gluconeogenesis and lipogenesis. It is 
also plausible that inhibition of SULT1E1 is a compen-
satory mechanism to counter the alteration of insulin 
signaling and derangement in glucose metabolism in 
patients with ALD (Supporting Fig. S4).
Our data also suggest that changes in the serum 
metabolic profiles depend on the timing of alcohol 
consumption, as indicated by the number of changes 
in metabolites in HD1 and HD2 samples (Supporting 
Table S3). To further test this hypothesis, we found 
that levels of several metabolites, notably in the BA 
pathway, demonstrated a downward trajectory follow-
ing alcohol abstinence (Fig. 5A,B). Whether we can 
use these metabolites as biomarkers to confirm alcohol 
abstinence should be further studied. The mechanistic 
illustration of the effect of alcohol on the dysregu-
lation of genes involving several metabolic pathways 
leading to alterations in serum metabolomic profiles 
was summarized in Fig. 7.
The strengths of our study are its prospective 
design and the inclusion of well-characterized Cs, 
HDs, and patients with AC. We acknowledge several 
limitations. First, we did not perform paired analy-
ses of samples from the same patients to determine 
the association between gene expression and serum 
metabolome. In clinical practice, it may be ethically 
impossible to conduct liver biopsy among healthy Cs, 
and it was impractical to perform a liver biopsy for 
all patients in our cohort. Second, although our data 
clearly showed metabolic signatures in patients with 
AC stratified by severity, the majority of our patients 
were those with decompensation (Child-Pugh B 
and C). Future studies with a larger sample size for 
patients with compensated AC (Child-Pugh A) may 
be needed to validate our results. Nonetheless, results 
from our studies may provide a new noninvasive diag-
nostic approach for ALD using serum metabolome 
profiling, especially conjugated BAs.
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